HAMBURG (dpa-AFX) - Evotec has received a major contract from the US Department of Defense for a platform solution for the production of biotherapeutics. Specifically, the contract is for the development of an accelerated solution for the development and production of monoclonal antibodies, as the MDax-listed company announced on Tuesday. In this way, the US government wants to improve its ability to respond to medical countermeasures based on biologics. The multi-year program award for the subsidiary Just - Evotec Biologics has a value of up to USD 39 million (EUR 36.4 million).

Evotec shares continued their recent stabilization attempt this morning at the broker Lang & Schwarz. They rose by two percent compared to the Xetra close. Just last week, the shares had fallen to a multi-year low before vague takeover fantasies led to a stabilization. Nevertheless, the share price is set to fall by around 60 percent in 2024./mis/tih